JP2021522242A5 - - Google Patents

Info

Publication number
JP2021522242A5
JP2021522242A5 JP2020559394A JP2020559394A JP2021522242A5 JP 2021522242 A5 JP2021522242 A5 JP 2021522242A5 JP 2020559394 A JP2020559394 A JP 2020559394A JP 2020559394 A JP2020559394 A JP 2020559394A JP 2021522242 A5 JP2021522242 A5 JP 2021522242A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
ring
nitrogen
Prior art date
Application number
JP2020559394A
Other languages
English (en)
Japanese (ja)
Other versions
JP7304892B2 (ja
JP2021522242A (ja
JPWO2019209759A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028607 external-priority patent/WO2019209759A1/en
Publication of JP2021522242A publication Critical patent/JP2021522242A/ja
Publication of JP2021522242A5 publication Critical patent/JP2021522242A5/ja
Publication of JPWO2019209759A5 publication Critical patent/JPWO2019209759A5/ja
Priority to JP2023092450A priority Critical patent/JP2023101824A/ja
Application granted granted Critical
Publication of JP7304892B2 publication Critical patent/JP7304892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559394A 2018-04-24 2019-04-23 抗増殖性化合物およびその使用 Active JP7304892B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023092450A JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661719P 2018-04-24 2018-04-24
US62/661,719 2018-04-24
PCT/US2019/028607 WO2019209759A1 (en) 2018-04-24 2019-04-23 Antiproliferation compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023092450A Division JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Publications (4)

Publication Number Publication Date
JP2021522242A JP2021522242A (ja) 2021-08-30
JP2021522242A5 true JP2021522242A5 (https=) 2022-04-13
JPWO2019209759A5 JPWO2019209759A5 (https=) 2022-04-13
JP7304892B2 JP7304892B2 (ja) 2023-07-07

Family

ID=66655429

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559394A Active JP7304892B2 (ja) 2018-04-24 2019-04-23 抗増殖性化合物およびその使用
JP2023092450A Pending JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023092450A Pending JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Country Status (27)

Country Link
US (4) US10815225B2 (https=)
EP (2) EP4043460B1 (https=)
JP (2) JP7304892B2 (https=)
KR (1) KR102813581B1 (https=)
CN (1) CN112236428B (https=)
AR (1) AR114496A1 (https=)
AU (1) AU2019261308B2 (https=)
BR (1) BR112020020940A2 (https=)
CA (1) CA3098335A1 (https=)
CY (1) CY1125433T1 (https=)
DK (2) DK3784666T3 (https=)
ES (2) ES2919572T3 (https=)
FI (1) FI4043460T3 (https=)
HR (2) HRP20241163T1 (https=)
HU (2) HUE067936T2 (https=)
IL (2) IL278142B2 (https=)
LT (1) LT3784666T (https=)
MX (1) MX2020011089A (https=)
PL (2) PL4043460T3 (https=)
PT (2) PT4043460T (https=)
RS (1) RS63281B1 (https=)
SG (1) SG11202009500QA (https=)
SI (1) SI3784666T1 (https=)
SM (1) SMT202200308T1 (https=)
TW (1) TWI813673B (https=)
WO (1) WO2019209759A1 (https=)
ZA (1) ZA202006071B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2919572T3 (es) 2018-04-24 2022-07-27 Merck Patent Gmbh Compuestos antiproliferación y usos de los mismos
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020236834A1 (en) * 2019-05-20 2020-11-26 Seshadri Raju Modified z stents for iliac vein stenting
US20230046892A1 (en) 2019-12-20 2023-02-16 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
WO2024073502A1 (en) * 2022-09-28 2024-04-04 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors
WO2025223536A1 (zh) * 2024-04-26 2025-10-30 正大天晴药业集团股份有限公司 稠合双环化合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE19840028A1 (de) 1998-09-02 2000-03-09 Max Planck Gesellschaft Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
AR073354A1 (es) 2008-07-31 2010-11-03 Genentech Inc Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
AR076014A1 (es) * 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
BR112012012905A2 (pt) * 2009-12-04 2017-03-01 Hoffmann La Roche derivados de difenil azepina como inibidores da reabsorção de monoamina
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20180118721A1 (en) * 2015-02-13 2018-05-03 Merck Patent Gmbh Pyrimidine derivatives
ES2919572T3 (es) 2018-04-24 2022-07-27 Merck Patent Gmbh Compuestos antiproliferación y usos de los mismos

Similar Documents

Publication Publication Date Title
JP2021522242A5 (https=)
JP2021522237A5 (https=)
AR044403A1 (es) Derivados de oximas y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
JP2018536648A5 (https=)
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
JP2015532295A5 (https=)
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
HRP20220710T1 (hr) Antiproliferacijski spojevi i njihova uporaba
JP2018535963A5 (https=)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JPWO2021143701A5 (https=)
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
JP2020510091A5 (https=)
RU2018102365A (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
SI2743266T1 (en) Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis
JP2020506951A5 (https=)
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
JP2016505586A5 (https=)
JP2017518959A5 (https=)
JP2016503797A5 (https=)
RU2012109554A (ru) Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
JP2008517923A5 (https=)